Researchers at the University of Turku developed a rapid point-of-care diagnostic test to detect ovarian cancer from blood samples in 30 minutes. The new test shows improved sensitivity and accuracy compared to conventional CA125 diagnostics.
A new two-stage surgical protocol delays the induced menopause caused by ovary removal, providing some ovarian cancer risk reduction while avoiding detrimental consequences. The study found that 69% of premenopausal women at high risk of ovarian cancer were interested in this alternative option.
Researchers developed a tumour gene test that accurately predicts ovarian cancer survival, outperforming age and cancer stage. The test identifies high-risk patients for personalized treatment options.
Tumors in ovarian cancer interact with platelets through broken blood vessel barriers, enabling metastasis. Organ-on-a-chip technology allows researchers to study this interaction and explore potential treatments.
A CUNY ISPH study reveals that ovarian cancer grows and evolves continuously, with mixtures of subclones accumulating mutations. The findings challenge previous simplistic models of discrete subtypes, offering a clearer picture of tumor heterogeneity.
Researchers analyzed how ovarian function in mice responded to various levels of glyphosate exposure and found increased ovarian weight and follicle number at highest exposure levels. However, the study did not uncover evidence that glyphosate affects the healthy functioning of ovaries.
L-Grb2 antisense oligodeoxynucleotide (L-Grb2) has promising antitumor activity in preclinical models of ovarian and uterine carcinoma, reducing angiogenesis and increasing apoptosis. L-Grb2's therapeutic efficacy suggests a potential new target for cancer treatment.
A global study led by Queen Mary University of London found that screening entire populations for breast and ovarian cancer genes can prevent millions more cases than current clinical practice. The research shows that cost-effective genetic testing can be implemented in high and upper-middle income countries to save lives.
A study by TGen has identified a drug, SP-2577, which can enable the immune system to attack ovarian cancer. The drug, also known as Seclidemstat, was developed to inhibit LSD1, a protein that is abundant in SCCOHT ovarian cancer.
A large-scale study found that young women with few eggs collected during IVF treatment have a higher risk of age-related diseases, including cardiovascular disease and osteoporosis. This increased risk is associated with early ovarian ageing and may be linked to an accelerated ageing process.
Researchers utilized a computational method to analyze the CDR3 regions of T-cell receptors from high-grade serous ovarian cancers. The study found that patients with low T-cell infiltration but diverse or focused repertoires had clinical outcomes similar to highly-infiltrated tumors. The authors identified the degree of divergence bet...
Researchers developed a new test, PrOTYPE, to classify high-grade serous ovarian cancer into four molecular subtypes. This test allows clinicians to tailor treatments to individual patients' tumours with over 95% accuracy.
A study published in Oncotarget reports that adoptive cell therapy in combination with checkpoint inhibitors improves T cell fold expansion and increases CD8 T cell tumor reactivity in patients with late-stage metastatic ovarian cancer. The authors suggest that combination immunotherapy may be a way forward for this purpose.
Researchers found that ovarian cancer patients with a modified BRCA1 gene do not respond better to platinum chemotherapy or have a better prognosis than those with the normal functioning gene. However, they did live longer on these treatments compared to those without any gene modifications.
A study by the Hubrecht Institute found that oviduct cells are more prone to develop into tumors than ovarian surface epithelium cells. This suggests a possible shift in treatment approach, with earlier removal of fallopian tubes considered as a preventive measure for high-risk patients.
Researchers have confirmed biological hallmarks of survival in tumor cells and identified two processes linked to high-grade serous carcinoma. Proteomics analysis reveals details about protein communication and function in cancerous cells, providing insights into the 'broken' machinery behind ovarian cancer.
A new study found that personalized ovarian cancer risk prediction reduces cancer worry and anxiety in women. Participants who received the personalized risk estimate were more likely to take preventative action and reduce their risk of developing ovarian cancer.
Researchers have discovered a new approach to overcome chemotherapy resistance in clear cell ovarian cancer by using low doses of 2-deoxy-D-glucose. The treatment has shown significant improvement in laboratory models and is expected to be safer for patients with reduced side effects.
Researchers have discovered that cancer cells use fats as an energy source when detached from their point of origin, and that limiting access to a specific enzyme may starve them of this resource. The study suggests that an existing drug could be repurposed to treat chemo-resistant ovarian cancer.
Researchers develop new type of immunotherapy targeting macrophages in omental fat, which appears to reduce ovarian cancer spread and tumour growth. The study shows promise for improving treatment outcomes, but further testing is needed.
Researchers at Dana-Farber Cancer Institute have identified two factors that predict which ovarian cancer patients will not benefit from a combination of immune checkpoint and PARP inhibitors. Patients with specific gene mutations or vigorous immune responses to the cancer are more likely to respond to the therapy.
A genetic study found that long-term statin use may be associated with a 40% reduction in ovarian cancer risk in the general population and those with BRCA1/2 gene faults. The research used Mendelian randomization to analyze thousands of people's genetic data.
Researchers developed a simple blood test that measures the body's immune response to improve ovarian cancer diagnosis. The test uses an immune marker for inflammation and cancer markers to detect epithelial ovarian cancer in blood, with results validated across two separate human trial cohorts.
Researchers at MUSC and UCSD found that autophagy genes work against tumors in certain types of ovarian cancer. The study validated the role of BECN1 and LC3B as tumor suppressors, shedding light on their potential as targets for treatment.
Researchers at the University of Oxford have identified six previously unknown cell types in human Fallopian tubes using single-cell RNA sequencing, which may lead to a screening tool for ovarian cancer. The discovery sheds new light on the complexity of ovarian cancers and could lead to personalized treatments.
A study from Ann & Robert H. Lurie Children's Hospital of Chicago defines the safest laparoscopic technique for removing ovaries in girls, resulting in better quality ovarian tissue for future transplantation. This technique minimizes damage and maximizes fertility preservation, increasing pregnancy rates after transplantation.
A new MRI tool has been developed and shown to be 90% accurate in distinguishing between malignant and benign ovarian cysts. This could lead to earlier treatment and improved outcomes for women with ovarian cancer, reducing the need for invasive surgery.
Researchers analyzed ovarian cells from young and old non-human primates to understand ovarian aging. They identified genes that could be used as biomarkers and point to therapeutic targets for diagnosing and treating female infertility and age-associated ovarian diseases.
A protein associated with ovarian cancer may contribute to the progression of Alzheimer's disease by impairing mitochondria function and causing neuronal damage. Researchers have identified OCIAD1 as a potential therapeutic target for the disease.
A study found that APLN overexpression correlates with worsened prognosis in ovarian cancer patients treated with bevacizumab. The researchers also identified a distinct gene signature associated with resistance development, paving the way for new treatment strategies.
Researchers at the University of Texas MD Anderson Cancer Center found that secondary tumor-reduction surgery followed by chemotherapy did not result in longer survival than chemotherapy alone. The study involved 240 patients with platinum-sensitive recurrent ovarian cancer and showed that complete tumor resection was associated with i...
Nami Therapeutics develops nanoparticles for targeted drug delivery, offering increased efficacy and reduced toxicity. The platform selectively targets ovarian cancer metastasis in the peritoneal cavity, improving survival rates.
A new study found that a blood test for CA125 levels can detect ovarian cancer in women with suspicious symptoms, with 10% of those with high levels diagnosed with the disease. The test also revealed higher risks of other cancers, such as pancreatic and lung cancer, among older women
A study by Dartmouth researchers found that a specific genetic subgroup of triple-negative breast cancer and ovarian cancer is vulnerable to heat shock protein 90 (HSP90) inhibitors. This discovery may lead to improved treatment strategies for patients with these cancers.
A laboratory study found that fibrosis, a natural stiffening of the ovaries, occurs with age and may be linked to ovarian cancer. Metformin, a diabetes drug, was shown to halt this process in some cases.
A Phase III trial validates the benefit of veliparib for patients with newly diagnosed, metastatic high-grade serous ovarian cancer. The combination therapy achieved a PFS of 23.5 months, compared to 17.3 months for the control arm.
A new trial shows that adding a PARP inhibitor to bevacizumab improves ovarian cancer patients' chances of responding to chemotherapy. The study found median progression-free survival of 22.1 months in the olaparib arm, compared to 16.6 months in the placebo group.
A new treatment using niraparib after conventional chemotherapy improves progression-free survival and reduces risk of relapse or death in patients with advanced ovarian cancer. The study, led by Dr. Antonio González Martín, found a significant reduction in risk of relapse, especially in patients with homologous recombination deficiency.
A new study found that women who experienced PTSD symptoms were at a higher risk of developing ovarian cancer, particularly those with high-grade serous histotype. Researchers analyzed data from the Nurses' Health Study II and found a significant association between PTSD and increased ovarian cancer risk.
A new study links elevated levels of FAK to the survival of cancer stem cells and DNA repair in ovarian cancer tumors, making them resistant to platinum chemotherapy. Researchers found that FAK inhibition can improve treatment response in mice with chemo-resistant tumors.
A study at the George Washington University Cancer Center found a novel pathway causing platinum resistance in ovarian cancer cells. The ERK/PHD2/HIF-1α axis regulates HIF-1α stability, leading to poor prognoses for patients.
Women with BRCA1/2 gene mutations are at high risk of developing ovarian cancer, with a lifetime risk of 39-44% for BRCA1 and 11-17% for BRCA2. A new review provides guidance on screening, preventive surgery, contraception and management of menopausal symptoms to reduce this risk.
Researchers at Houston Methodist and MD Anderson Cancer Center have found a new immunotherapy to treat ovarian and pancreatic cancers by blocking the action of MFAP5 protein. This protein promotes tumor growth and reduces survival rates in patients with these cancers.
Researchers at Penn State College of Medicine have identified a potential therapeutic target for high-grade serous ovarian cancer cells by preventing a protein from doing its job. Inhibiting this protein led to a halt in cell division and may be an effective strategy for future therapies.
Researchers at CRCHUM found that Ran protein is essential for ovarian cancer cells to migrate and invade healthy tissues. Inhibiting Ran expression can break down RhoA, a protein necessary for cell migration, leading to a loss of cancer cells' ability to move.
A new study shows that niraparib can extend life for women with ovarian cancer who have undergone multiple rounds of chemotherapy. The study found that 27% of patients responded well to the drug and averaged 9.2 months until disease progression, offering hope for a meaningful treatment option.
A study by Columbia University researchers found that limiting ovarian cancer surgery to high-volume hospitals could improve survival but also reduce access for many rural and underserved patients. In fact, nearly 35% of low-volume hospitals had better-than-expected outcomes at 60 days and 51% at 2 years.
Researchers at University of Montreal Hospital Research Centre develop a two-step combination therapy to destroy cancer cells. They manipulate cellular aging to force cancer cells into senescence, then use senolysis to eliminate them. This strategy shows superior therapeutic effectiveness on ovarian cancer patients.
Researchers have identified eight protein biomarkers that enable accurate differentiation between endometrioid and high-grade serous ovarian carcinomas. This breakthrough could lead to more precise diagnosis and tailored treatment for patients, reducing the risk of undertreatment or overtreatment.
Researchers have successfully used circulating tumor DNA to monitor patient responses and find targeted treatments for ovarian cancer. The technique can detect genomic alterations in late-stage cancers, even when biopsies are difficult or impossible, and identify poor-responding patients after chemotherapy.
Researchers have identified 34 genes associated with an increased risk of developing the earliest stages of ovarian cancer. The study uses alternative splicing analysis to pinpoint these genes, which can help identify women at high risk and pave the way for new therapies.
A recent study found that fewer than a quarter of breast cancer patients and a third of ovarian cancer patients underwent genetic testing for cancer-associated mutations. The research, which analyzed data from over 83,000 women diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014, revealed substantial...
Researchers found that Chop expression is higher in T cells from ovarian cancer patients, and high nuclear levels of Chop are associated with poor clinical responses. Blocking Chop or ER stress may help improve T cell-based immunotherapy treatments.
Researchers at the University of Manchester have identified a new class of drugs that can stop ovarian cancer cells from growing. The PARG inhibitors target weaknesses in DNA replication, making them sensitive to these treatments.
A new diagnostic tool has been developed to detect ovarian cancer earlier, with high sensitivity and specificity rates. The test uses liquid biopsy proteomics to identify unique protein signatures in uterine fluid, promising improved detection rates for young women at high risk of developing the disease.
A new experimental drug, 673A, targets and annihilates stem-like ovarian cancer cells that cause recurrence. The treatment, combined with chemotherapy, resulted in significantly greater survival rates in a mouse model of ovarian cancer.
Researchers developed AI software that predicts ovarian cancer prognosis and treatment effectiveness, outperforming existing methods by up to four times. The technology can stratify patients based on CT scan texture differences, enabling personalized medicine.
A new study found sufficient evidence to raise concerns about prenatal BPA exposure's effects on ovarian development and function. The researchers believe their findings are relevant to both fetal and women's health, particularly in relation to infertility and endocrine disrupting chemicals.
A new study has identified a pair of genes that can mimic the effects of BRCA proteins, potentially making tumor cells susceptible to PARP inhibitors. The researchers found that targeting these genes could improve treatment options for people with breast or ovarian cancer caused by BRCA defects.
Researchers at Brigham and Women's Hospital have discovered two new genetic targets, APEX2 and FEN1, which show promise as potential treatments for hereditary breast and ovarian cancers. The study's findings suggest that inhibiting these enzymes could complement existing Parp inhibitors and address drug resistance in BRCA-driven cancer.